Lysogene (ENXTPA:LYS) - Share price, News & Analysis

LYS fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

LYS Stock Overview

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders.

Risk Analysis

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€12M)

Lysogene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lysogene
Historical stock prices
Current Share Price	€0.71
52 Week High	€3.25
52 Week Low	€0.63
Beta	0.68
1 Month Change	-3.40%
3 Month Change	-38.90%
1 Year Change	-69.59%
3 Year Change	-63.78%
5 Year Change	-87.02%
Change since IPO	-89.57%

Shareholder Returns

	LYS	FR Biotechs	FR Market
7D	1.4%	-0.4%	3.7%
1Y	-69.6%	-39.4%	-3.7%

Return vs Industry: LYS underperformed the French Biotechs industry which returned -39.4% over the past year.

Return vs Market: LYS underperformed the French Market which returned -3.7% over the past year.

Price Volatility

Is LYS's price volatile compared to industry and market?
LYS volatility
LYS Average Weekly Movement	8.9%
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.9%
10% most volatile stocks in FR Market	10.0%
10% least volatile stocks in FR Market	3.4%

Stable Share Price: LYS is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: LYS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2009	22	Karen Pignet-Aiach	https://www.lysogene.com

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases.

Lysogene Fundamentals Summary

How do Lysogene's earnings and revenue compare to its market cap?
LYS fundamental statistics
Market Cap	€12.21m
Earnings (TTM)	-€13.61m
Revenue (TTM)	€7.22m

1.7x

P/S Ratio

-0.9x

P/E Ratio

Is LYS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
LYS income statement (TTM)
Revenue	€7.22m
Cost of Revenue	€0
Gross Profit	€7.22m
Other Expenses	€20.83m
Earnings	-€13.61m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.79
Gross Margin	100.00%
Net Profit Margin	-188.52%
Debt/Equity Ratio	25.8%

How did LYS perform over the long term?

See historical performance and comparison

Valuation

Is Lysogene undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.8x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LYS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYS's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: LYS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: LYS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LYS's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: LYS is good value based on its Price-To-Book Ratio (1.8x) compared to the FR Biotechs industry average (2.8x).

Future Growth

How is Lysogene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

48.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lysogene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Lysogene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

12.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LYS is currently unprofitable.

Growing Profit Margin: LYS is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: LYS is unprofitable, but has reduced losses over the past 5 years at a rate of 12.5% per year.

Accelerating Growth: Unable to compare LYS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LYS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: LYS has a negative Return on Equity (-200.19%), as it is currently unprofitable.

Financial Health

How is Lysogene's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LYS's short term assets (€26.0M) exceed its short term liabilities (€19.8M).

Long Term Liabilities: LYS's short term assets (€26.0M) exceed its long term liabilities (€1.8M).

Debt to Equity History and Analysis

Debt Level: LYS has more cash than its total debt.

Reducing Debt: LYS's debt to equity ratio has increased from 12.7% to 25.8% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if LYS has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LYS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is Lysogene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LYS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LYS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LYS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LYS's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LYS has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure

CEO

Karen Pignet-Aiach (50 yo)

13.33yrs

Tenure

€2,588,100

Compensation

Mrs. Karen Pignet-Aiach, MBA, has been Chairman of Lysogene S.A. since May 22, 2019 and is its Chief Executive Officer since May 20, 2019. Mrs. Pignet-Aiach serves as Chief Executive Officer and Director o...

CEO Compensation Analysis

Compensation vs Market: Karen's total compensation ($USD2.77M) is above average for companies of similar size in the French market ($USD285.89K).

Compensation vs Earnings: Karen's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: LYS's management team is considered experienced (3.7 years average tenure).

Board Members

Experienced Board: LYS's board of directors are considered experienced (3.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/28 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31